OBJECTIVE: This study was designed to evaluate vitamin D status with separate determination of 25-OH D2 and 25-OH D3 and its relationship to vitamin D binding protein (VDBP) in patients with chronic kidney disease (CKD) and long-term haemodialysis patients (HD). METHODS: 45 CKD patients, 103 HD patients, and 25 controls (C) were included. Plasma vitamin D concentrations were determined using chromatography and VDBP in serum and urine in CKD using enzyme immunoassay. RESULTS: Plasma vitamin D levels were lower in CKD (30.16 ± 16.74 ng/mL) and HD (18.85 ± 15.85 ng/mL) versus C (48.72 ± 18.35 ng/mL), P < 0.0001. 25-OH D3 was the dominant form of vitamin D. Serum VDBP was higher in CKD (273.2 ± 93.8 ug/mL) versus C (222 ± 87.6 ug/mL) and HD (213.8 ± 70.9 ug/mL), P = 0.0003. Vitamin D/VDBP ratio was the highest in C and the lowest in HD; however, there was no correlation between vitamin D and VDBP. Urinary concentration of VDBP in CKD (0.25 ± 0.13 ug/mL) correlated with proteinuria (r = 0.43, P = 0.003). CONCLUSIONS: Plasma levels of vitamin D are decreased in CKD patients and especially in HD patients. 25-OH D3 was the major form of vitamin D. Despite urinary losses of VDBP, CKD patients had higher serum VDBP concentrations, indicating compensatory enhanced production. Vitamin D binding protein is not involved in vitamin D deficiency.

Department of Nephrology 1st Faculty of Medicine Charles University Prague and General University Hospital Prague U Nemocnice 499 2 128 08 Prague Czech Republic

Haemodialysis Centre University Hospital Hradec Kralove Sokolská 581 500 05 Hradec Kralove Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague and General University Hospital Prague U Nemocnice 499 2 128 01 Prague Czech Republic

Zobrazit více v PubMed

Holick M. F. Vitamin D deficiency. The New England Journal of Medicine. 2007;357:266–281. doi: 10.1056/nejmra070553. PubMed DOI

Holick M. F. Vitamin D status: measurement, interpretation, and clinical application. Annals of Epidemiology. 2009;19(2):73–78. doi: 10.1016/j.annepidem.2007.12.001. PubMed DOI PMC

Binkley N., Ramamurthy R., Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinology and Metabolism Clinics of North America. 2010;39(2):287–301. doi: 10.1016/j.ecl.2010.02.008. PubMed DOI PMC

Nigwekar S. U., Bhan I., Thadhani R. Ergocalciferol and cholecalciferol in CKD. The American Journal of Kidney Diseases. 2012;60(1):139–156. doi: 10.1053/j.ajkd.2011.12.035. PubMed DOI

González E. A., Sachdeva A., Oliver D. A., Martin K. J. Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study. American Journal of Nephrology. 2004;24(5):503–510. doi: 10.1159/000081023. PubMed DOI

LaClair R. E., Hellman R. N., Karp S. L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. American Journal of Kidney Diseases. 2005;45(6):1026–1033. doi: 10.1053/j.ajkd.2005.02.029. PubMed DOI

Levin A., Bakris G. L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International. 2007;71(1):31–38. doi: 10.1038/sj.ki.5002009. PubMed DOI

Jean G., Charra B., Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. Journal of Renal Nutrition. 2008;18(5):395–399. doi: 10.1053/j.jrn.2008.04.003. PubMed DOI

Echida Y., Mochizuki T., Uchida K., Tsuchiya K., Nitta K. Risk factors for vitamin D deficiency in patients with chronic kidney disease. Internal Medicine. 2012;51(8):845–850. doi: 10.2169/internalmedicine.51.6897. PubMed DOI

Dusilová-Sulková S., Šafránek R., Vávrová J., Horáček J., Pavlíková L., Palička V. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. International Urology and Nephrology. 2015;47(1):169–176. doi: 10.1007/s11255-014-0842-7. PubMed DOI

Yousefzadeh P., Shapses S. A., Wang X. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. International Journal of Endocrinology. 2014;2014:6. doi: 10.1155/2014/981581.981581 PubMed DOI PMC

Taskapan H., Wei M., Oreopoulos D. G. 25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. International Urology and Nephrology. 2006;38(2):323–329. doi: 10.1007/s11255-006-0081-7. PubMed DOI

Melamed M. L., Thadhani R. I. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clinical Journal of the American Society of Nephrology. 2012;7(2):358–365. doi: 10.2215/cjn.04040411. PubMed DOI PMC

Speeckaert M., Huang G., Delanghe J. R., Taes Y. E. C. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clinica Chimica Acta. 2006;372(1-2):33–42. doi: 10.1016/j.cca.2006.03.011. PubMed DOI

Chun R. F. New perspectives on the vitamin D binding protein. Cell Biochemistry and Function. 2012;30(6):445–456. doi: 10.1002/cbf.2835. PubMed DOI

Brown A. J., Coyne D. W. Bioavailable vitamin D in chronic kidney disease. Kidney International. 2012;82(1):5–7. doi: 10.1038/ki.2012.135. PubMed DOI

Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999;96(4):507–515. doi: 10.1016/S0092-8674(00)80655-8. PubMed DOI

Leheste J.-R., Rolinski B., Vorum H., et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. American Journal of Pathology. 1999;155(4):1361–1370. doi: 10.1016/s0002-9440(10)65238-8. PubMed DOI PMC

Nykjaer A., Fyfe J. C., Kozyraki R., et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3 . Proceedings of the National Academy of Sciences of the United States of America. 2001;98(24):13895–13900. doi: 10.1073/pnas.241516998. PubMed DOI PMC

Piquette C. A., Robinson-Hill R., Webster R. O. Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin. Journal of Leukocyte Biology. 1994;55(3):349–354. PubMed

Adebanjo O. A., Moonga B. S., Haddad J. G., Huang C. L.-H., Zaidi M. A possible new role for vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+ sensing at low physiological concentrations. Biochemical and Biophysical Research Communications. 1998;249(3):668–671. doi: 10.1006/bbrc.1998.9037. PubMed DOI

Wallace A. M., Gibson S., de la Hunty A., Lamberg-Allardt C., Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids. 2010;75(7):477–488. doi: 10.1016/j.steroids.2010.02.012. PubMed DOI

Moon H.-W., Cho J.-H., Hur M., et al. Comparison of four current 25-hydroxyvitamin D assays. Clinical Biochemistry. 2012;45(4-5):326–330. doi: 10.1016/j.clinbiochem.2011.12.025. PubMed DOI

Heijboer A. C., Blankenstein M. A., Kema I. P., Buijs M. M. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clinical Chemistry. 2012;58(3):543–548. doi: 10.1373/clinchem.2011.176545. PubMed DOI

Michaud J., Naud J., Ouimet D., et al. Reduced hepatic synthesis of calcidiol in uremia. Journal of the American Society of Nephrology. 2010;21(9):1488–1497. doi: 10.1681/asn.2009080815. PubMed DOI PMC

Doorenbos C. R. C., de Cuba M. M., Vogt L., et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. The Journal of Steroid Biochemistry and Molecular Biology. 2012;128(1-2):56–61. doi: 10.1016/j.jsbmb.2011.09.002. PubMed DOI

van Hoof H. J. C., de Sévaux R. G. L., van Baelen H., et al. Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. European Journal of Endocrinology. 2001;144(4):391–396. doi: 10.1530/eje.0.1440391. PubMed DOI

Anic G. M., Weinstein S. J., Mondul A., Mannisto S., Albanes D. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer. PLoS ONE. 2014;9(7) doi: 10.1371/journal.pone.0102966.e102966 PubMed DOI PMC

Mirković K., Doorenbos C. R. C., Dam W. A., et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS ONE. 2013;8(2) doi: 10.1371/journal.pone.0055887.e55887 PubMed DOI PMC

Mendel C. M. The free hormone hypothesis: a physiologically based mathematical model. Endocrine Reviews. 1989;10(3):232–274. doi: 10.1210/edrv-10-3-232. PubMed DOI

Bhan I., Powe C. E., Berg A. H., et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney International. 2012;82(1):84–89. doi: 10.1038/ki.2012.19. PubMed DOI PMC

Jean G., Terrat J. C., Vanel T., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clinical Practice. 2008;110(1):c58–c65. doi: 10.1159/000151534. PubMed DOI

Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clinical Journal of the American Society of Nephrology. 2011;6(4):913–921. doi: 10.2215/cjn.06040710. PubMed DOI

Slatopolsky E., Brown A., Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney International. 1999;56(73):S14–S19. doi: 10.1046/j.1523-1755.1999.07104.x. PubMed DOI

Xie Z., Santora A. C., Shapses S. A., Wang X. Vitamin D binding protein and vitamin D levels. International Journal of Endocrinology. 2014;2014:2. doi: 10.1155/2014/638263.638263 PubMed DOI PMC

Ross A. C., Manson J. E., Abrams S. A., et al. Clarification of DRIs for calcium and vitamin D across age groups. Journal of the American Dietetic Association. 2011;111(10):p. 1467. doi: 10.1016/j.jada.2011.08.022. PubMed DOI